 |
245 Diseases |  |
54 Trials |
|
54 Trials |  |
1419 News |  |
| «12345678910111213...2021» |
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Cyclophosphamide, Etoposide, and Intermediate-Dose of Carboplatin; An Efficient Preparative Regimen for Autologous Transplantation for Patients with Lymphoma, a Good Alternative to Those Based on Carmustine. Experience with 108 Patients (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4564;
Thirty-five (32.4%) had HL, 35 (32.4 %) NHL (28 diffuse large B cell, 7 follicular), 29 (26,9%) had MCL, and 9 (8.3%) had other lymphomas. 34% of HL patients and 48% of cases were transplanted in CR1 after being refractory to first line therapy, while 44% and 14% of HL and NHL respectively had active disease at the time of transplantation.
- Adcetris (brentuximab vedotin) / Seagen, Takeda
Evaluation of Pulmonary Toxicities in Lymphoma Patients Receiving Brentuximab Vedotin (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4143;
This study is an effort to raise awareness of the incidence of Bv-induced pulmonary toxicity and describe the potential risk factors associated with this adverse event. Further real world studies in larger and diverse patient populations are necessary to better characterize the incidence and risk factors associated with Bv-associated pulmonary toxicities.
- Safety of Autologous Hematopoietic Stem Cell Transplantation in Patients over 75 Years Old. Single Center Experience Serving a Minority Population (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3422;
We did not find a statistically significant increase in morbidity or mortality for patients 75-80 years of age undergoing auto-HSCT compared with patients 55-65 years old. To our knowledge this is the largest cohort to date demonstrating the safety of auto-HSCT in this elderly population.
- methotrexate IV / Generic mfg., ifosfamide / Generic mfg.
Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG) (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_2987;
Consolidation was part of first-line treatment in 58 (35%) pts: WBRT in 39 and carmustine-thiotepa/conditioned ASCT in 19; 106 pts did not receive consolidation due to PD during first-line chemo (n=96), pt refusal (2), poor conditions (4) or per protocol (4)...Salvage chemo consisted of HD-ifosfamide-based chemo (R-IE, RICE, DeVIC) in 20 pts, rechallenging with HD-MTX-based chemo (same regimen or ± other drugs) in 25, direct myeloablative chemo and ASCT in 3, single drugs in 10; 17 pts responsive to salvage chemo received consolidative ASCT (n=12) or WBRT...Pts experiencing LR can achieve long-lasting second remission, especially when retreatment with HD-MTX-based chemo is feasible. Efficacy of salvage therapy appears to be independent of the first-line treatment.
- melphalan / Generic mfg., carmustine / Generic mfg.
Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs) (GWCC - Hall A1) - Nov 5, 2021 - Abstract #ASH2021ASH_2329;
Our data suggests that heavily pretreated, predominantly triple-class refractory, patients relapsing after BiAbs may still have good outcomes when sequentially treating with other immunological/T cell-directed therapeutics such as BiAbs and CAR T cells. Studying the appropriate sequence of these treatments is of paramount importance as BiAbs are expected to become part of the standard of care for RRMM patients.
- Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience
Autologous Stem Cell Transplantation after Conditioning with Chidamide Plus Carmustine, Etoposide, Cytarabine, and Cyclophosphamide (Chi-BEAC) for Treatment of High-Risk and Relapsed/Refractory Aggressive Lymphoma: Multi-Center, Single-Arm, Open-Label Phase II Clinical Trial (GWCC - B401-B402, Level 4) - Nov 5, 2021 - Abstract #ASH2021ASH_2124;
Conclusions : This study showed that inclusion of the HDACi chidamide in conditioning regimen for ASCT greatly increased the PFS and OS, especially in patients with T&NK-NHL, and revealed an acceptable safety profile for refractory and relapsed lymphoma patients. Therefore, chidamide-containing conditioning regimen may be a great choice for patients with refractory and relapsed lymphoma, and awaits further confirmation by additional large-scale multi-center investigations.
- Venclexta (venetoclax) / Roche, AbbVie
Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) (GWCC - B401-B402, Level 4) - Nov 5, 2021 - Abstract #ASH2021ASH_2120;
P1/2
Baseline characteristics and safety data for all three cohorts are presented in Table 1. The majority were male (79%) and had stage IV disease (79%).
- | Mustargen (mechlorethamine) / Recordati
Trial completion date, Trial primary completion date, Metastases: SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells (clinicaltrials.gov) - Nov 1, 2021
P1, N=10, Recruiting, Sponsor: General Oncology, Inc.
The majority were male (79%) and had stage IV disease (79%). Trial completion date: Jan 2023 --> May 2023 | Trial primary completion date: Jul 2022 --> Nov 2022
- | carmustine / Generic mfg.
Journal: Morphological and Calcium Signaling Alterations of Neuroglial Cells in Cerebellar Cortical Dysplasia Induced by Carmustine. (Pubmed Central) - Oct 28, 2021
Carmustine-treated mice were affected in their motor coordination and balance. Cerebellar dysplasias and heterotopias were more frequently found in lobule X. Morphology of BG cells and astrocytes was affected, as were their spontaneous [Ca] transients in slice preparation and in vitro.
- carmustine / Generic mfg.
[VIRTUAL] DR REDDYS: TACTH for Lymphomas - Carmustine-based regimen takes place in conditioning prior to autologous HSCT / Autologous HSCT for Lymphomas - Carmustine-based regimen takes place in conditioning prior to autologous HSCT () - Oct 27, 2021 - Abstract #HEMO2021HEMO_666;
Cerebellar dysplasias and heterotopias were more frequently found in lobule X. Morphology of BG cells and astrocytes was affected, as were their spontaneous [Ca] transients in slice preparation and in vitro. Sponsored by DR REDDYS
- | Jakafi (ruxolitinib) / Novartis, Incyte, Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience
New P2 trial: Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen (clinicaltrials.gov) - Oct 21, 2021
P2, N=50, Recruiting, Sponsor: Chinese PLA General Hospital
- || Clinical, Journal: Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry. (Pubmed Central) - Oct 20, 2021
This analysis suggests that, in patients with lymphoma receiving pre-transplant regimens such as carmustine, etoposide, cytarabine and melphalan, PBSCs stored at 4°C for up to 6 days can be used safely in centers with no cryopreservation facility. However, the kinetics of hematopoietic recovery showed a significant, albeit small, delay in engraftment for both neutrophils and platelets, which favors the use of cryopreservation if available.
- | carmustine / Generic mfg.
Enrollment open: Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases (clinicaltrials.gov) - Oct 19, 2021
P2, N=28, Recruiting, Sponsor: Thomas Jefferson University
However, the kinetics of hematopoietic recovery showed a significant, albeit small, delay in engraftment for both neutrophils and platelets, which favors the use of cryopreservation if available. Not yet recruiting --> Recruiting
- || Zynyz (retifanlimab-dlwr) / Incyte
New P1 trial, Combination therapy, IO biomarker: Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma (clinicaltrials.gov) - Oct 19, 2021
P1, N=50, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- | Istodax (romidepsin) / Astellas, BMS
Trial completion date, Trial primary completion date: A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 18, 2021
P2, N=47, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Jul 2021 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Jul 2023
- | carmustine / Generic mfg.
$RDY Dr. Reddy';s Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market https://t.co/PebXzk7da4 (Twitter) - Oct 15, 2021
- | Jakafi (ruxolitinib) / Novartis, Incyte, Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience
New P1/2 trial: Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 13, 2021
P1/2, N=50, Recruiting, Sponsor: Chinese PLA General Hospital
- | VBI-1901 / VBI Vaccines
Trial completion date, Trial primary completion date: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects (clinicaltrials.gov) - Oct 12, 2021
P1/2, N=38, Active, not recruiting, Sponsor: VBI Vaccines Inc.
Trial completion date: Jul 2021 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Jul 2023 Trial completion date: Jul 2021 --> Mar 2022 | Trial primary completion date: Oct 2020 --> Mar 2022
- | Venclexta (venetoclax) / Roche, AbbVie
Trial completion date, Trial primary completion date: OSU-17225: Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 6, 2021
P1/2, N=19, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Trial completion date: Jul 2021 --> Mar 2022 | Trial primary completion date: Oct 2020 --> Mar 2022 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- || cisplatin / Generic mfg., methotrexate / Generic mfg.
Clinical, Journal: First-line therapy, autologous stem-cell transplantation, and post-transplantation maintenance in the management of newly diagnosed mantle cell lymphoma. (Pubmed Central) - Sep 26, 2021
Final approval of this guidance document was obtained from the Stem Cell Transplant Advisory Committee. These recommendations apply to all cases of transplantation-eligible newly diagnosed mcl:■ Alternating cycles of r-chop (rituximab plus cyclophosphamide-doxorubicin-vincristine-prednisolone) and r-dhap [rituximab plus dexamethasone-high-dose cytarabine-cisplatin] is the recommended first-line treatment for symptomatic patients newly diagnosed with mcl before autologous stem-cell transplantation (asct).■ Rituximab plus hyperfractionated cyclophosphamide-vincristine-doxorubicin-dexamethasone (r-hypercvad), alternating with methotrexate and cytarabine, is not recommended for the treatment of patients with newly diagnosed mcl.■ beam (carmustine-etoposide-cytarabine-melphalan), beac (carmustine-etoposide-cytarabine-cyclophosphamide), and total-body irradiation-based regimens are reasonable conditioning options for patients with mcl who have responded to first-line therapy and who are undergoing asct.■ Maintenance therapy with rituximab is recommended for patients with newly diagnosed mcl who have undergone asct.
- | mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Enrollment change: Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT (clinicaltrials.gov) - Sep 23, 2021
P2, N=11, Completed, Sponsor: Stanford University
These recommendations apply to all cases of transplantation-eligible newly diagnosed mcl:■ Alternating cycles of r-chop (rituximab plus cyclophosphamide-doxorubicin-vincristine-prednisolone) and r-dhap [rituximab plus dexamethasone-high-dose cytarabine-cisplatin] is the recommended first-line treatment for symptomatic patients newly diagnosed with mcl before autologous stem-cell transplantation (asct).■ Rituximab plus hyperfractionated cyclophosphamide-vincristine-doxorubicin-dexamethasone (r-hypercvad), alternating with methotrexate and cytarabine, is not recommended for the treatment of patients with newly diagnosed mcl.■ beam (carmustine-etoposide-cytarabine-melphalan), beac (carmustine-etoposide-cytarabine-cyclophosphamide), and total-body irradiation-based regimens are reasonable conditioning options for patients with mcl who have responded to first-line therapy and who are undergoing asct.■ Maintenance therapy with rituximab is recommended for patients with newly diagnosed mcl who have undergone asct. N=38 --> 11
- [VIRTUAL] Autologous haematopoietic stem cell transplantation of patients with aggressive relapsing-remitting multiple sclerosis: a Danish single-centre experience (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2435;
AHSCT is an effective and relatively safe treatment with few serious AEs and no mortality in Danish RRMS patients. However, randomized clinical trials comparing AHSCT with other high efficacy MS disease modifying therapies are still needed.
- | temozolomide / Generic mfg.
New P2 trial: hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (clinicaltrials.gov) - Sep 21, 2021
P2, N=16, Not yet recruiting, Sponsor: Andrew Sloan, MD
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
CNS relapses in young high-risk DLBCL patients - a collaborative analysis of LYSA and GLA (A7) - Sep 20, 2021 - Abstract #DGHO2021DGHO_65;
Young hr pts receiving R- (Mega) CHOEP including rituximab and etoposide crossing the blood-brain barrier but no systemic CNS prophylaxis experienced CNS relapse in a significant number of cases. R-ACVBP including consolidation might decrease the rate of CNS relapse and should be discussed for pts at high risk.
- | temozolomide / Generic mfg.
Journal: Brain-targeted, drug-loaded solid lipid nanoparticles against glioblastoma cells in culture. (Pubmed Central) - Sep 9, 2021
In addition, targeted nanoparticles were more uptaken by MCT-1 expressing brain cells. This study indicated that BCNU and TMZ loaded SLNs could act as a useful anticancer system for targeted GBM therapy.
- ifosfamide / Generic mfg.
[VIRTUAL] High-Dose Chemotherapy Regimens in Therapy of NHL DLBCL: A SingleCenter Experience () - Sep 6, 2021 - Abstract #SOHO2021SOHO_647;
The major adverse event in both groups was myelosuppression with higher but tolerable treatment-related toxicity for patients in the DexaBEAM group. Considering the small sample size, our data suggest that R-ICE salvage chemotherapy is superior to R-Dexa BEAM for patients with R/R NHL DLBCL for remission induction prior to autologous transplantation.
- | cyclophosphamide / Generic mfg., cytarabine / Generic mfg., carmustine / Generic mfg.
New trial: AutoMS-Swe: Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden (clinicaltrials.gov) - Aug 30, 2021
P, N=200, Recruiting, Sponsor: Uppsala University
- || methotrexate IV / Generic mfg., methotrexate / Generic mfg.
Review, Journal: Consolidation Therapy in Primary Central Nervous System Lymphoma. (Pubmed Central) - Aug 25, 2021
For patients who are not transplant candidates and that do not accept the risk of cognitive decline from the radiotherapy, we typically offer consolidation high-dose cytarabine, provided the patient understands the high risk of relapse. For these patients, a clinical trial is strongly recommended.
- | ribavirin / Generic mfg., cisplatin / Generic mfg., bicalutamide / Generic mfg.
Journal: Development and validation of a six-RNA binding proteins prognostic signature and candidate drugs for prostate cancer. (Pubmed Central) - Aug 22, 2021
Using the Connectivity Map, we finally predicted 3 drugs including, ribavirin, carmustine, and carbenoxolone. In summary, we identified six-RBP gene signature and 3 potential drugs against PCa, which might promote the individualized treatment strategies and further improve the quality of life among PCa patients.
- || Valchlor (mechlorethamine gel) / Helsinn, Recordati
Review, Journal: Topical treatments for early-stage mycosis fungoides using Grading Recommendations Assessment, Development and Evaluation (GRADE) criteria: A systematic review. (Pubmed Central) - Aug 20, 2021
Two searches yielded 1252 references; 26 met the inclusion criteria and included literature on nitrogen mustard, retinoids, corticosteroids, carmustine, fluorouracil, methotrexate-laurocapram, hexadecylphosphocholine, peldesine, ingenol mebutate, topical methotrexate with oxygen flow-assisted LP3 carrier, and resiquimod...For most outcomes of interest, the GRADE certainty for topical therapies for early-stage MF was low. Further randomized controlled trials and inclusion of quality of life indicators are needed.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Preclinical, Trial completion date, Trial primary completion date: Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 16, 2021
P2, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Further randomized controlled trials and inclusion of quality of life indicators are needed. Recruiting --> Active, not recruiting | Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022
- | carmustine / Generic mfg.
Journal: Molecular docking of potential cytotoxic alkylating Carmustine derivatives 2-chloroethylnitrososulfamides analogues of 2-chloroethylnitrosoureas. (Pubmed Central) - Aug 13, 2021
By superimposing the results of molecular docking, analysis of data from the study of electrophilia based on load transfer ECT and publications on CENS, we can predict that inter-strand crosslink is likely to occur between the Guanine dG22 of strand B and the Cytosine dC3 of strand A, located in the poly dA-poly dT segment end within the narrow minor groove of the DNA target (2DND). The molecular docking study was a preliminary approach to understand the therapeutic mode of action of CENS.
- | carmustine / Generic mfg.
Journal: Effect of Superparamagnetic DMSO@γ-Fe₂O₃ Combined with Carmustine on Cervical Cancer. (Pubmed Central) - Aug 8, 2021
For the control, gamma-Fe₂O₃ hyperthermia, chemotherapy, and DMSO@γ-Fe₂O₃ combined chemotherapy groups, the apoptosis rates of the cervical cancer cells were 1.4%, 18.6%, 24.12%, and 38.97%, respectively. DMSO@γ-Fe₂O₃ nanomagnetic fluid thermotherapy combined with the chemotherapeutic drug carmustine exerted a noticeable toxic effect on the cervical cancer cells, and DMSO@γ-Fe₂O₃ significantly enhanced the killing effect of carmustine on cervical cancer cells.
- [VIRTUAL] Autologous haematopoietic stem cell transplantation of patients with aggressive relapsing-remitting multiple sclerosis: a Danish single-centre experience (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_529;
AHSCT is an effective and relatively safe treatment with few serious AEs and no mortality in Danish RRMS patients. However, randomized clinical trials comparing AHSCT with other high efficacy MS disease modifying therapies are still needed.
- | lomustine / Generic mfg., carmustine / Generic mfg.
Retrospective data, Journal: Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma-a retrospective study from the BSBMT (BEAM versus LEAM). (Pubmed Central) - Jul 7, 2021
However, randomized clinical trials comparing AHSCT with other high efficacy MS disease modifying therapies are still needed. No abstract available
- | Journal: Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. (Pubmed Central) - Jul 4, 2021
The combination of Y-anti-CD45 with BEAM and AHCT was feasible and tolerable in patients with relapsed and refractory lymphoma. The use of anti-CD45 ARC as an adjunct to HCT regimens or in combination with novel therapies/immunotherapies should be further explored based on these and other data.
- || Clinical, Journal: Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. (Pubmed Central) - Jun 28, 2021
Although BEAM followed by AHCT is effective, it is associated with significant organ toxicities, especially in patients aged ≥70 years. Interventions to mitigate toxicities while maintaining efficacy are much needed.
- | Simulect (basiliximab) / Novartis, 90Y basiliximab - National Cancer Institute / Bethesda, Starasid (cytarabine ocfosfate) / Nippon Kayaku
Trial completion date, Trial primary completion date: Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma (clinicaltrials.gov) - Jun 25, 2021
P2, N=33, Recruiting, Sponsor: City of Hope Medical Center
Interventions to mitigate toxicities while maintaining efficacy are much needed. Trial completion date: Apr 2023 --> Nov 2023 | Trial primary completion date: Apr 2023 --> Nov 2023
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, Journal: R-BEAM versus Reduced Intensity Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma. (Pubmed Central) - Jun 24, 2021
R-BEAM regimen seems feasible, and results in equivalent rates of long-term OS, relapse, NRM and RFS compared to RIC. However, significantly higher rate of severe acute GVHD was noticed.
- || isotretinoin oral / Generic mfg., carmustine / Generic mfg.
Clinical, Journal: Pilot Study of a Novel Therapeutic Approach for Refractory Advanced Stage Folliculotropic Mycosis Fungoides. (Pubmed Central) - Jun 24, 2021
We report here a high response rate using a novel therapeutic regimen combining interferon gamma, isotretinoin in low dose and topical carmustine, and in some cases concomitant skin-directed therapies, among 6 consecutive patients with refractory folliculotropic mycosis fungoides with stages IB through IIIB who had previously failed both topical and systemic therapies. The potential mechanisms of this multimodality approach are discussed.
- | methotrexate / Generic mfg.
Journal: Outcomes of Autologous Stem Cell Transplant Consolidation in Primary CNS Lymphoma: A Mayo Clinic Experience. (Pubmed Central) - Jun 24, 2021
All patients received high-dose methotrexate-based induction therapy...Disease response status before transplant significantly impacted the outcomes as those in complete remission(CR) had an OS at 2 years post-transplant of 94.7% (68.1-99.2) in BEAM group and 90.5% (67.0-97.5) in BCNU/TT group as compared to those in partial response (PR), 57.1% (17.2-83.7) in BCNU/TT group, and 50.0% (11.1-80.4) in the BEAM group, respectively (p <0.0001). Our retrospective cohort adds to the currently available literature and identifies the disease status before transplant as a significant factor impacting survival.
- || Campath (alemtuzumab) / Sanofi
Clinical, Journal: BEAM-Campath allogeneic stem cell transplant for patients with relapsed/refractory lymphoma - High incidence of long term mixed donor-recipient chimerism and the response to donor lymphocyte infusions. (Pubmed Central) - Jun 24, 2021
The frequent development of myeloid MDRC, demonstrates that BEAM-Campath is a non-myeloablative conditioning regimen in almost a third of patients. MDRCt is associated with reduced NRM, but neither MDRCtor MDRCm are associated with increased GvHD or relapse.
- | carmustine / Generic mfg.
Journal: Cell Models for Birth Defects Caused by Chloroethyl Nitrosourea-Induced DNA Lesions. (Pubmed Central) - Jun 24, 2021
Here we generate DNA lesions in NIH/3T3 cells to mimic defects in fetus triggered by 3-Bis(2-chloroethyl)-1-nitrosourea (BCNU, carmustine)...Taken together, all these experiments demonstrate we have successfully established normal cell models for birth defects caused by BCNU-mediated DNA damages. The model can not only guide the development of effective and low-toxicity anticancer drugs, but also be of great significance for the study of neonatal malformation triggered by BCNUs.
- || Trial completion date, Trial primary completion date: Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jun 24, 2021
P2, N=60, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
The model can not only guide the development of effective and low-toxicity anticancer drugs, but also be of great significance for the study of neonatal malformation triggered by BCNUs. Trial completion date: Oct 2021 --> Oct 2023 | Trial primary completion date: Oct 2021 --> Oct 2023
- | carmustine / Generic mfg.
Journal: Molecular Insight into Adsorption Affinities of Carmustine Drug on Boron and Nitrogen Doped Functionalized Single-walled Carbon Nanotubes Using Density Functional Theory Including Dispersion Correction Calculations and Molecular Dynamics Simulation. (Pubmed Central) - Jun 22, 2021
Moreover, molecular dynamics simulation is performed to investigate the dynamics behavior of the drug molecules on the nitrogen-doped functionalized carbon nanotube (f-NNT) and functionalized carbon nanotube (f-CNT). The higher average calculated electrostatic and van der Waals energies as well as higher number of intermolecular hydrogen bonds in BNU-f-NNT in comparison with BNU-f-CNT model suggest the more effectual interaction between drug molecules and nitrogen-doped functionalized carbon nanotube.
- | bendamustine / Generic mfg.
Retrospective data, Journal: Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. (Pubmed Central) - Jun 22, 2021
Despite the high rate of acute renal failure KDIGO III (32%), treatment-related mortality was not increased with the BeEAM regimen. A prospective randomized trial will be necessary to confirm the beneficial effect of the BeEAM regimen in MCL patients undergoing ASCT.
- || Clinical, Journal: Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation. (Pubmed Central) - Jun 22, 2021
In the subgroup analysis, FTM was not inferior to FBM in patients with pulmonary disease prior allo-HCT, lymphoid malignancies, and higher comorbidity index. In conclusion, the reduced-intensity FBM and FTM conditioning protocols show adequate antineoplastic efficacy and are suitable for patients with impaired lung function.
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi
Trial completion, Trial completion date: NCI-2013-00701: O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas (clinicaltrials.gov) - Jun 16, 2021
P1/2, N=12, Completed, Sponsor: Fred Hutchinson Cancer Research Center
In conclusion, the reduced-intensity FBM and FTM conditioning protocols show adequate antineoplastic efficacy and are suitable for patients with impaired lung function. Active, not recruiting --> Completed | Trial completion date: Dec 2027 --> Jan 2021
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE ERA OF NOVEL THERAPIES- A RETROSPECTIVE ANALYSIS BY POLISH LYMPHOMA RESEARCH GROUP. () - Jun 11, 2021 - Abstract #ICML2021ICML_584;
Long-terms PFS suggests that autoHSCT may have curative potential in a subset of patients with FL. Prior ETF and Deauville score of ≥3 in PET-CT before transplantation are adverse factors for OS.
- | temozolomide / Generic mfg.
Journal: Chemotherapy for Glioma (Pubmed Central) - Jun 8, 2021
Although temozolomide administered orally or intravenously represents the standard of care for malignant gliomas, its efficacy is unsatisfactory...Carmustine wafers are clinically available local chemotherapeutic agents...In addition, recent progress in convection-enhanced delivery of chemotherapeutics against gliomas has also been reported. Development of an alternative strategy to effectively deliver drugs to the tumor site may improve the efficacy of chemotherapy against gliomas in the near future.